Literature DB >> 25035556

Psychiatric morbidity and quality of life in vitiligo patients.

Podaralla Ramakrishna1, Tenali Rajni1.   

Abstract

BACKGROUND: Vitiligo has underlying mental illness but mostly not diagnosed and never used psychiatric medication. Hence, the problem persists affecting mostly the individual's quality of life. AIM: Assessing the quality of life, level of depression, and self-esteem of patients with vitiligo and give psychiatric medication for underlying mental illness.
MATERIALS AND METHODS: The study conducted at Owaisi Hospital Research Centre, Hyderabad. The patients registered for dermatologist consultation were also registered for consultation with psychiatrist to rule out any mental illness after detailed evaluation using standardized scales.
RESULTS: Patients suffering with vitiligo had depression and low self-esteem; their quality of life was disturbed.
CONCLUSION: The findings provide the role of Mental Health Professionals involved in the field of dermatology for the patients suffering with vitiligo.

Entities:  

Keywords:  Depression; quality of life; self-esteem; vitiligo

Year:  2014        PMID: 25035556      PMCID: PMC4100418          DOI: 10.4103/0253-7176.135385

Source DB:  PubMed          Journal:  Indian J Psychol Med        ISSN: 0253-7176


INTRODUCTION

Skin is a sensory organ responsive to emotional stimuli and its appearance greatly influences body image and self-esteem.[12] Vitiligo has severe psychological and social problems. Currently it is estimated that emotional factors are associated in at least one-third of patients with skin conditions.[3] There is a common opinion that many cases of skin disease are caused by psychological stress, or are related to certain personality traits or represent a complication of a psychiatric disorder. This opinion is partly supported by research evidence.[4567] Mental health in vitiligo patients is poor[8] and leads to a significant decrease in quality of life.[9] Vitiligo has a major impact on quality of life of patients, many feel stigmatized by their condition.[10] Majority of vitiligo patients experienced anxiety, depression, frustration, and embarrassment when meeting strangers and disturbances noted in interpersonal relations or beginning a new sexual relationship. Papadopoulos et al. (1999)[11] have shown that counseling can help improve body image, self-esteem, and quality of life of patients with vitiligo.

MATERIALS AND METHODS

Materials used were Vitiligo Area Severity Index (VASI), Rosenberg Self Esteem Scale (RSES), Dermatology Life Quality Index Questionnaire (DLQI). Hamilton Depression Rating Scale (HDRS). Depression assessment scale.

RESULTS

The sample consisted of 22.6% (n = 12) males; females accounted for 77.4% (n = 41). The subjects were graduates and postgraduates. This group was 37.7% (n = 20) of the sample. Unemployed people are seen at the highest frequency in the sample at 39.6% (n = 21) and they were employed. Semiprofessionals accounted for 3.8% (n = 2). Psychiatric mobility was 79.2% (n = 42). Major depressive disorder accounted for 56.6% (n = 30). Social phobia had the highest prevalence at 67.9% (n = 36) 45.3% (n = 24) of people had both major depressive disorder and social phobia. Suicidality was seen in 28.3% (n = 15) of patients, high risk in 7.5% (n = 4), and low risk suicidality in 11 subjects (20.8%). Among the other co-morbidities found were panic disorder at 11.3% (n = 6) and obsessive compulsive disorder at 3.8% (n = 2). It is seen that 30 of 53 patients had major depressive disorder. Forty-five out of total patients had vitiligo that was exposed. Chi-square test on this data shows that exposed vitiligo and major depressive disorder are significantly related. Thirty six of total patients had social phobia. All the patients with social phobia had vitiligo that was exposed. Chi-square test on this data shows that exposed vitiligo and social phobias are significantly related (Sig. <0.05). Fifteen of the total patients had suicidality. The marital status of patients was seen for association with DLQI and self-esteem. The mean DLQI in unmarried people was 9.04 with SD of 5.616. The mean self-esteem in unmarried people was 15.24 with SD of 4.702. The DLQI score of unmarried patients of vitiligo is significantly higher than that in those who are married (Sig. 0.003). The self-esteem in unmarried people with vitiligo was significantly lower than that in the married people (Sig.0.054).

CONCLUSIONS

Depression was high in middle and lower socioeconomic classes compared to the upper class. Suicidality decreased with increasing socioeconomic class. Longer the time after the appearance of vitiligo lesser the psychiatric comorbidity. People who find that treatment is helpful have a better quality of life than those who do not. All the people with dark skin had major depressive disorder. They also had higher incidence of social phobia, higher risk of suicide, and lower self-esteem, compared to lighter skinned individuals. Quality of life was better for people with lighter skin. Vitiligo lesions are associated with high incidence of major depressive disorder and social phobia. Lesions were strongly associated with high incidence of major depressive disorder, high incidence of social phobia, lower quality of life, and lower self-esteem. An overall psychiatric morbidity of 79.2% was seen. Major depressive disorder accounted for 56.6% and social phobia for 67.9% respectively. Lower quality of life in patients with vitiligo was associated with higher comorbid mental illness.
  11 in total

Review 1.  Stressful life events and skin diseases: disentangling evidence from myth.

Authors:  A Picardi; D Abeni
Journal:  Psychother Psychosom       Date:  2001 May-Jun       Impact factor: 17.659

2.  Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome.

Authors:  D Parsad; R Pandhi; S Dogra; A J Kanwar; B Kumar
Journal:  Br J Dermatol       Date:  2003-02       Impact factor: 9.302

Review 3.  Psychosomatic dermatology. Is it relevant?

Authors:  M A Gupta; J J Voorhees
Journal:  Arch Dermatol       Date:  1990-01

4.  [Psychiatric morbidity and quality of life in Vitiligo: a case controlled study].

Authors:  Anwar Mechri; Montassar Amri; Abdool Aslham Douarika; Bel Hadj Ali Hichem; Béchir Zouari; Jameleddine Zili
Journal:  Tunis Med       Date:  2006-10

5.  Stressful life events, social support, attachment security and alexithymia in vitiligo. A case-control study.

Authors:  A Picardi; P Pasquini; M S Cattaruzza; P Gaetano; C F Melchi; G Baliva; D Camaioni; A Tiago; D Abeni; M Biondi
Journal:  Psychother Psychosom       Date:  2003 May-Jun       Impact factor: 17.659

6.  Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy.

Authors:  L Papadopoulos; R Bor; C Legg
Journal:  Br J Med Psychol       Date:  1999-09

Review 7.  Psychodermatology: an update.

Authors:  M A Gupta; A K Gupta
Journal:  J Am Acad Dermatol       Date:  1996-06       Impact factor: 11.527

8.  Psychosomatic concepts in dermatology. A dermatologist-psychoanalyst's viewpoint.

Authors:  C S Koblenzer
Journal:  Arch Dermatol       Date:  1983-06

9.  Psychosomatic factors in first-onset alopecia areata.

Authors:  A Picardi; P Pasquini; M S Cattaruzza; P Gaetano; G Baliva; C F Melchi; M Papi; D Camaioni; A Tiago; T Gobello; M Biondi
Journal:  Psychosomatics       Date:  2003 Sep-Oct       Impact factor: 2.386

10.  DLQI scores in vitiligo: reliability and validity of the Persian version.

Authors:  Shahin Aghaei; Manouchehr Sodaifi; Peyman Jafari; Nazila Mazharinia; Andrew Y Finlay
Journal:  BMC Dermatol       Date:  2004-08-04
View more
  11 in total

1.  Vitiligo: Patient stories, self-esteem, and the psychological burden of disease.

Authors:  P E Grimes; M M Miller
Journal:  Int J Womens Dermatol       Date:  2018-01-08

2.  Assessment of quality of life in vitiligo patients attending a tertiary care hospital - A cross sectional study.

Authors:  Suman Baidya; Pranjal Dey; Rakesh Mohanty
Journal:  Ind Psychiatry J       Date:  2021-06-04

3.  Erratum: psychiatric morbidity and quality of life in vitiligo patients: erratum.

Authors: 
Journal:  Indian J Psychol Med       Date:  2015 Jan-Mar

Review 4.  Suicide in India: Distinct Epidemiological Patterns and Implications.

Authors:  Starlin Vijay Mythri; Johann Alex Ebenezer
Journal:  Indian J Psychol Med       Date:  2016 Nov-Dec

5.  Chronic diseases among vitiligo patients. A case control study.

Authors:  Abdullah O Al Houssien; Rana O Al Houssien; Waleed Al Ajroush; Hassan S Al Kahtani
Journal:  Saudi Med J       Date:  2017-04       Impact factor: 1.484

6.  Clinico-Epidemiological Profile and Treatment Pattern of Vitiligo in Selected Dermatological Clinics of Mekelle City, Northern Ethiopia.

Authors:  Afewerki Gebremeskel Tsadik; Goitom Fitsum Legesse; Desilu Mahari Desta; Brhane Teklebrhan Assefa; Hailekiros Gebretsadik Kidanemariam; Meles Tekie Gidey
Journal:  Dermatol Res Pract       Date:  2020-05-30

7.  Psychosocial Effects of Vitiligo: A Systematic Literature Review.

Authors:  Khaled Ezzedine; Viktoria Eleftheriadou; Heather Jones; Kristen Bibeau; Fiona I Kuo; Daniel Sturm; Amit G Pandya
Journal:  Am J Clin Dermatol       Date:  2021-09-23       Impact factor: 7.403

Review 8.  Integrin Regulated Autoimmune Disorders: Understanding the Role of Mechanical Force in Autoimmunity.

Authors:  Souradeep Banerjee; Ritika Nara; Soham Chakraborty; Debojyoti Chowdhury; Shubhasis Haldar
Journal:  Front Cell Dev Biol       Date:  2022-03-18

9.  Vitiligo and Psychiatric Morbidity: A Profile from a Vitiligo Clinic of a Rural-based Tertiary Care Center of Eastern India.

Authors:  Somenath Sarkar; Tanusree Sarkar; Arnab Sarkar; Swagata Das
Journal:  Indian J Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.494

10.  Public Knowledge and Attitudes towards Vitiligo: A Survey in Mekelle City, Northern Ethiopia.

Authors:  Afewerki Gebremeskel Tsadik; Mezgebe Zeru Teklemedhin; Tesfay Mehari Atey; Meles Tekie Gidey; Desilu Mahari Desta
Journal:  Dermatol Res Pract       Date:  2020-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.